Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)RWD on T-DXd for gastric cancer in Japan

被引：0

作者：

Hisato Kawakami ^{[1
]}

Koki Nakanishi ^{[2
]}

Akitaka Makiyama ^{[3
]}

Hirotaka Konishi ^{[4
]}

Satoshi Morita ^{[5
]}

Yukiya Narita ^{[6
]}

Naotoshi Sugimoto ^{[7
]}

Keiko Minashi ^{[8
]}

Motohiro Imano ^{[9
]}

Rin Inamoto ^{[10
]}

Yasuhiro Kodera ^{[2
]}

Hiroki Kume ^{[11
]}

Keita Yamaguchi ^{[11
]}

Wataru Hashimoto ^{[12
]}

Kei Muro ^{[6
]}

机构：

[1] Kindai University Faculty of Medicine,Department of Medical Oncology

[2] Nagoya University Graduate School of Medicine,Department of Gastroenterological Surgery

[3] Gifu University Hospital,Cancer Center

[4] Kyoto Prefectural University of Medicine,Division of Digestive Surgery

[5] Kyoto University Graduate School of Medicine,Department of Biomedical Statistics and Bioinformatics

[6] Aichi Cancer Center Hospital,Department of Clinical Oncology

[7] Osaka International Cancer Institute,Department of Genetic Oncology

[8] Chiba Cancer Center,Division of Gastroenterology

[9] Kindai University Faculty of Medicine,Department of Surgery

[10] Saitama Cancer Center,Department of Gastroenterology

[11] Daiichi Sankyo Co. Ltd.,Oncology Medical Science Department I

[12] Daiichi Sankyo Co. Ltd.,Data Intelligence Department

来源：

Gastric Cancer | 2025年 / 28卷 / 1期

关键词：

Effectiveness; Gastric cancer; HER2-positive; Japan; Post-marketing surveillance; Real world; Safety; Third- or later-line; Trastuzumab-deruxtecan (T-DXd);

D O I：

10.1007/s10120-024-01555-w

中图分类号：

学科分类号：

摘要：

引用

页码：51 / 61

页数：10

共 50 条

[1] Correction: Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)
Hisato Kawakami
Koki Nakanishi
Akitaka Makiyama
Hirotaka Konishi
Satoshi Morita
Yukiya Narita
Naotoshi Sugimoto
Keiko Minashi
Motohiro Imano
Rin Inamoto
Yasuhiro Kodera
Hiroki Kume
Keita Yamaguchi
Wataru Hashimoto
Kei Muro
Gastric Cancer, 2025, 28 (1) : 62 - 62
[2] Retrospective cohort study to evaluate the efficacy and safety of T-DXd in HER2-positive unresectable advanced or recurrent gastric or gastroesophageal junction cancer: EN-DEAVOR study.
Nakanishi, Koki
Kodera, Yasuhiro
Kawakami, Hisato
Makiyama, Akitaka
Konishi, Hirotaka
Morita, Satoshi
Narita, Yukiya
Sugimoto, Naotoshi
Minashi, Keiko
Imano, Motohiro
Inamoto, Rin
Kume, Hiroki
Yamaguchi, Keita
Hashimoto, Wataru
Muro, Kei
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 274 - 274
[3] Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
Kotani, Daisuke
Shitara, Kohei
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[4] Trastuzumab deruxtecan in previously treated advanced HER2-positive gastric cancer
Pamuk, Aylin
Kuetting, Fabian
Alakus, Hakan
Bruns, Christiane
ONKOLOGE, 2021, 27 (01): : 74 - 76
[5] Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer
Shitara, Kohei
Baba, Eishi
Fujitani, Kazumasa
Oki, Eiji
Fujii, Satoshi
Yamaguchi, Kensei
GASTRIC CANCER, 2021, 24 (04) : 780 - 789
[6] Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer
Kohei Shitara
Eishi Baba
Kazumasa Fujitani
Eiji Oki
Satoshi Fujii
Kensei Yamaguchi
Gastric Cancer, 2021, 24 : 780 - 789
[7] Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
Masahiko Aoki
Satoru Iwasa
Narikazu Boku
Gastric Cancer, 2021, 24 : 567 - 576
[8] Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
Aoki, Masahiko
Iwasa, Satoru
Boku, Narikazu
GASTRIC CANCER, 2021, 24 (03) : 567 - 576
[9] The use of trastuzumab in Japanese patients with HER2-positive advanced or metastatic gastric cancer
Sawaki, A.
Ohashi, Y.
Omuro, Y.
Satoh, T.
Hamamoto, Y.
Boku, N.
Miyata, Y.
Takiuchi, H.
Ohtsu, A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[10] Trastuzumab-deruxtecan in HER2 positive advanced gastric or gastroesophageal junction cancer after previous treatment with trastuzumab
Duval, Jeanne
Zaanan, Aziz
BULLETIN DU CANCER, 2023, 110 (7-8) : 739 - 740

← 1 2 3 4 5 →